Novo Nordisk (NVO) shares declined following results from the REDEFINE-4 trial, where CagriSema achieved 23.0% weight loss at 84 weeks versus 25.5% for Eli Lilly’s (LLY) tirzepatide (Zepbound). Zepbound has become the efficacy benchmark in obesity, and CagriSema’s relative underperformance makes the commercial path for the product more challenging. The outcome reinforces LLY’s increasing dominance in the category as NVO falls behind.
Key Takeaways from Consumer Edge Phoenix pharmacy claims data:
- Claims data highlights Zepbound’s strength across key patient metrics and its lead relative to existing commercial NVO products:
- Zebound 12-month persistence remains >50%, materially above semaglutide-based products.
- Competitive leakage from Zepbound is limited, with low base churn and only a small share of discontinuations driven by switching to branded competitors.
- Given tirzepatide’s real-world strength and the REDEFINE-4 results, CagriSema faces a meaningful challenge in narrowing the existing competitive gap.
While CagriSema is experimental and not yet observable in pharmacy claims data, Phoenix pharmacy data provides real-world visibility into the performance of Zepbound and Wegovy, contextualizing the competitive bar Novo is attempting to clear.
Phoenix data highlights Zepbound’s strength across several key utilization metrics. Beyond sustained growth in total volume, Zepbound has demonstrated strength across longitudinal metrics:
- Average 12-month persistence for Zepbound is over 50%, well above historical expectations for the weight-loss population and levels observed for semaglutide-based therapies (~40% for Ozempic and ~30% for Wegovy). Importantly, retention has remained stable even as the treated population has expanded, supporting continued accumulation of active patients.

- Overall competitive switching remains low. Observed monthly churn off Zepbound has tracked in the 3-4% range in recent periods, materially below the 8-10% monthly churn observed for Wegovy. Among discontinuations, the majority represent exits from the GLP-1 obesity class rather than switching to competing branded therapies, suggesting limited competitive leakage from Zepbound.


Against this backdrop, CagriSema represented an important opportunity for Novo to introduce a therapy capable of resetting competitive dynamics – a goal that appears more distant following the outcome of the REDEFINE-4 trial. When CagriSema or other next-generation Novo therapies reach market, Consumer Edge claims data will allow for direct tracking of uptake, retention, and switching relative to incumbents.
One thought on “REDEFINE-4 in Context: Widening Gap between NVO and LLY in Obesity Market”
Comments are closed.